The adverse pharmacology of calcineurin inhibitors and their impact on hepatitis C recurrence after liver transplantation: implications for clinical practice

References

• Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin. Liver Dis. 14(1), 1–21, vii (2010).
   PubMedGoogle Scholar
• Trotter JF. Hot-topic debate on hepatitis C virus: the type of immunosuppression matters. Liver Transpl. 17(Suppl. 3), S20–S23 (2011).
   PubMed Web of Science ®Google Scholar
• Rosen HR. Clinical practice. Chronic hepatitis C infection. N. Engl. J. Med. 364(25), 2429–2438 (2011).
   PubMed Web of Science ®Google Scholar
• Terrault NA, Shiffman ML, Lok AS et al.; A2ALL Study Group. Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl. 13(1), 122–129 (2007).
   Web of Science ®Google Scholar
• Watt K, Veldt B, Charlton M. A practical guide to the management of HCV infection following liver transplantation. Am. J. Transplant. 9(8), 1707–1713 (2009).
   PubMed Web of Science ®Google Scholar
• Berenguer M, Prieto M, Rayón JM et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 32(4 Pt 1), 852–858 (2000).
   PubMed Web of Science ®Google Scholar
• Ciesek S, Wedemeyer H. Immunosuppression, liver injury and post-transplant HCV recurrence. J. Viral Hepat. 19(1), 1–8 (2012).
   Google Scholar
• Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl. Surg. 5(4 Suppl. 1), S107–S114 (1999).
   PubMedGoogle Scholar
• Starzl TE, Iwatsuki S, Shaw BW Jr, Gordon RD, Esquivel CO. Immunosuppression and other nonsurgical factors in the improved results of liver transplantation. Semin. Liver Dis. 5(4), 334–343 (1985).
   Google Scholar
• The US Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N. Engl. J. Med. 331(17), 1110–1115 (1994).
   PubMed Web of Science ®Google Scholar
• Perry I, Neuberger J. Immunosuppression: towards a logical approach in liver transplantation. Clin. Exp. Immunol. 139(1), 2–10 (2005).
   PubMed Web of Science ®Google Scholar
• Mueller XM. Drug immunosuppression therapy for adult heart transplantation. Part 1: immune response to allograft and mechanism of action of immunosuppressants. Ann. Thorac. Surg. 77(1), 354–362 (2004).
   PubMed Web of Science ®Google Scholar
• Oo YH, Dudley T, Nightingale P, Haydon G, Mutimer D. Tacrolimus and cyclosporin doses and blood levels in hepatitis C and alcoholic liver disease patients after liver transplantation. Liver Transpl. 14(1), 81–87 (2008).
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Mukherjee U. A comprehensive review of immunosuppression used for liver transplantation. J. Transplant. 2009, 701464 (2009).
   Google Scholar
• Kahan BD. Cyclosporine. N. Engl. J. Med. 321(25), 1725–1738 (1989).
   PubMed Web of Science ®Google Scholar
• Starzl TE, Koep L, Porter KA et al. Decline in survival after liver transplantation. Arch. Surg. 115(7), 815–819 (1980).
   PubMedGoogle Scholar
• Starzl TE, Klintmalm GB, Porter KA, Iwatsuki S, Schröter GP. Liver transplantation with use of cyclosporin a and prednisone. N. Engl. J. Med. 305(5), 266–269 (1981).
   PubMed Web of Science ®Google Scholar
• Calne RY. Liver transplantation. Ann. Clin. Res. 13(4-5), 327–335 (1981).
   Google Scholar
• Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin. J. Am. Soc. Nephrol. 4(2), 481–508 (2009).
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Mueller EA, van Bree JB et al. Cyclosporine pharmacokinetics and variability from a microemulsion formulation – a multicenter investigation in kidney transplant patients. Transplantation 58(6), 658–663 (1994).
   PubMed Web of Science ®Google Scholar
• Noble S, Markham A. Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral). Drugs 50(5), 924–941 (1995).
   PubMed Web of Science ®Google Scholar
• Tedesco D, Haragsim L. Cyclosporine: a review. J. Transplant. 2012, 230386 (2012).
   PubMedGoogle Scholar
• Williams D, Haragsim L. Calcineurin nephrotoxicity. Adv. Chronic Kidney Dis. 13(1), 47–55 (2006).
   Google Scholar
• Ojo AO, Held PJ, Port FK et al. Chronic renal failure after transplantation of a nonrenal organ. N. Engl. J. Med. 349(10), 931–940 (2003).
   PubMed Web of Science ®Google Scholar
• European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 344(8920), 423–428 (1994).
   PubMed Web of Science ®Google Scholar
• Meier-Kriesche HU, Li S, Gruessner RW et al. Immunosuppression: evolution in practice and trends, 1994–2004. Am. J. Transplant. 6(5 Pt 2), 1111–11131 (2006).
   PubMed Web of Science ®Google Scholar
• Wiesner RH. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. Transplantation 66(4), 493–499 (1998).
   Web of Science ®Google Scholar
• Nakagawa M, Sakamoto N, Tanabe Y et al. Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology 129(3), 1031–1041 (2005).
   PubMed Web of Science ®Google Scholar
• Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 38(5), 1282–1288 (2003).
   PubMed Web of Science ®Google Scholar
• Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl. 14(Suppl. 2), S36–S44 (2008).
   PubMed Web of Science ®Google Scholar
• Ishii N, Watashi K, Hishiki T et al. Diverse effects of cyclosporine on hepatitis C virus strain replication. J. Virol. 80(9), 4510–4520 (2006).
   PubMed Web of Science ®Google Scholar
• Hirano K, Ichikawa T, Nakao K et al. Differential effects of calcineurin inhibitors, tacrolimus and cyclosporin a, on interferon-induced antiviral protein in human hepatocyte cells. Liver Transpl. 14(3), 292–298 (2008).
   Google Scholar
• Pan Q, Metselaar HJ, de Ruiter P et al. Calcineurin inhibitor tacrolimus does not interfere with the suppression of hepatitis C virus infection by interferon-α. Liver Transpl. 16(4), 520–526 (2010).
   PubMed Web of Science ®Google Scholar
• Mercer DF, Schiller DE, Elliott JF et al. Hepatitis C virus replication in mice with chimeric human livers. Nat. Med. 7(8), 927–933 (2001).
   PubMed Web of Science ®Google Scholar
• Sandgren EP, Palmiter RD, Heckel JL, Daugherty CC, Brinster RL, Degen JL. Complete hepatic regeneration after somatic deletion of an albumin-plasminogen activator transgene. Cell 66(2), 245–256 (1991).
   PubMed Web of Science ®Google Scholar
• Kneteman NM, Asthana S, Lewis J et al. Impact of calcineurin inhibitors with or without interferon on hepatitis C virus titers in a chimeric mouse model of hepatitis C virus infection. Liver Transpl. 18(1), 38–44 (2012).
   Google Scholar
• Charlton MR, Thompson A, Veldt BJ et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 53(1), 317–324 (2011).
   PubMed Web of Science ®Google Scholar
• Golden-Mason L, Bambha KM, Cheng L et al.; Virahep-C Study Group. Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C. Hepatology 54(5), 1559–1569 (2011).
   Google Scholar
• Cescon M, Grazi GL, Cucchetti A et al. Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation. Liver Transpl. 15(7), 782–789 (2009).
   Google Scholar
• Firpi RJ, Zhu H, Morelli G et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl. 12(1), 51–57 (2006).
   PubMed Web of Science ®Google Scholar
• Selzner N, Renner EL, Selzner M et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation 88(10), 1214–1221 (2009).
   PubMed Web of Science ®Google Scholar
• Vero V, Senzolo M, Pasulo L et al.; AISF RECOLT-C Group. Is the primary immunosuppressive drug (cyclosporin A or tacrolimus) playing a role on the response to antiviral treatment for post-transplant HCV recurrence? J. Hepatol. 54(Suppl. 1), S235 (2011).
   Google Scholar
• Kim RD, Mizuno S, Sorensen JB, Schwartz JJ, Fujita S. Impact of calcineurin inhibitors on hepatitis C recurrence after liver transplantation. Dig. Dis. Sci. 57(2), 568–572 (2012).
   Google Scholar
• Carrión JA, Navasa M, García-Retortillo M et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 132(5), 1746–1756 (2007).
   PubMed Web of Science ®Google Scholar
• Berenguer M, Aguilera V, Prieto M et al. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients. Liver Transpl. 12(5), 762–767 (2006).
   PubMed Web of Science ®Google Scholar
• Oton E, Barcena R, Castillo M et al. Hepatitis C virus recurrence after liver transplantation: influence of immunosuppressive regimens on viral load and liver histology. Transplant. Proc. 38(8), 2499–2501 (2006).
   Google Scholar
• Samonakis DN, Triantos CK, Thalheimer U et al. Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl. 11(4), 386–395 (2005).
   PubMed Web of Science ®Google Scholar
• Irish WD, Arcona S, Bowers D, Trotter JF. Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database. Am. J. Transplant. 11(8), 1676–1685 (2011).
   PubMed Web of Science ®Google Scholar
• Zervos XA, Weppler D, Fragulidis GP et al. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. Transplantation 65(8), 1044–1046 (1998).
   Google Scholar
• Martin P, Busuttil RW, Goldstein RM et al. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Liver Transpl. 10(10), 1258–1262 (2004).
   Google Scholar
• Firpi RJ, Soldevila-Pico C, Morelli GG et al. The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study. Dig. Dis. Sci. 55(1), 196–203 (2010).
   Google Scholar
• Levy G, Grazi GL, Sanjuan F et al. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transpl. 12(10), 1464–1472 (2006).
   PubMed Web of Science ®Google Scholar
• Berenguer M, Aguilera V, San Juan F et al. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients. Transplantation 90(11), 1204–1209 (2010).
   Google Scholar
• McAlister VC, Haddad E, Renouf E, Malthaner RA, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am. J. Transplant. 6(7), 1578–1585 (2006).
   PubMed Web of Science ®Google Scholar
• Haddad E, McAlister VC, Renouf E et al. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst. Rev. 4, CD005161 (2006).
   Google Scholar
• Wiesner RH. Long-term comparison of tacrolimus versus cyclosporine in liver transplantation. The US FK Study Group. Transplant. Proc. 30(4), 1399–1400 (1998).
   Google Scholar
• Veldt BJ, Poterucha JJ, Watt KD et al. Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am. J. Transplant. 9(6), 1406–1413 (2009).
   PubMed Web of Science ®Google Scholar
• Foxton MR, Quaglia A, Muiesan P et al. The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. Am. J. Transplant. 6(8), 1922–1929 (2006).
   PubMed Web of Science ®Google Scholar
• Sherman KE, Flamm SL, Afdhal NH et al.; ILLUMINATE Study Team. Response-guided telaprevir combination treatment for hepatitis C virus infection. N. Engl. J. Med. 365(11), 1014–1024 (2011).
   PubMed Web of Science ®Google Scholar
• Poordad F, McCone J Jr, Bacon BR et al.; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364(13), 1195–1206 (2011).
   PubMed Web of Science ®Google Scholar
• Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 54(1), 20–27 (2011).
   PubMed Web of Science ®Google Scholar
• Carrión JA, Martínez-Bauer E, Crespo G et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J. Hepatol. 50(4), 719–728 (2009).
   PubMed Web of Science ®Google Scholar
• Torresi J, Johnson D, Wedemeyer H. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J. Hepatol. 54(6), 1273–1285 (2011).
   PubMed Web of Science ®Google Scholar
• Meuleman P, Hesselgesser J, Paulson M et al. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology 48(6), 1761–1768 (2008).
   PubMed Web of Science ®Google Scholar
• Castroagudín JF, Molina E, Varo E. Calcineurin inhibitors in liver transplantation: to be or not to be. Transplant. Proc. 43(6), 2220–2223 (2011).
   Google Scholar